- Home
- INDO vs RFL Comparison
INDO vs RFL Comparison
Compare INDO & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | INDO | RFL |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | Indonesia | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Real Estate |
| Sector | Energy | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.1M | 61.1M |
| IPO Year | 2018 | 2017 |
Fundamental Metrics
Financial Performance| Metric | INDO | RFL |
|---|---|---|
| Price | $4.62 | $1.49 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 3.5M | 89.3K |
| Earning Date | 01-01-0001 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $917,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 43.96 |
| 52 Week Low | $2.21 | $1.12 |
| 52 Week High | $8.50 | $3.19 |
Technical Indicators
Market Signals| Indicator | INDO | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 49.85 | 71.85 |
| Support Level | $2.77 | $1.41 |
| Resistance Level | $5.12 | $1.64 |
| Average True Range (ATR) | 0.98 | 0.10 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 12.98 | 73.17 |
Price Performance
Historical ComparisonAbout INDO Indonesia Energy Corporation Limited
Indonesia Energy Corp Ltd is an oil and gas exploration and production company focused on Indonesia. The company is an independent energy company engaged in the oil and gas business and holds two oil and gas assets through its subsidiaries in Indonesia: The Kruh Block and the Citarum Block. It has also identified a potential third exploration block known as the Rangkas area. . Its portfolio consists of Kruh Block and Citarum Block. The company generates its revenue from oil and gas sales.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.